- Gary M. Pfeiffer Elected to Board of Directors -
TETERBORO, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced that it completed its previously-announced
leadership succession process, with Surya N. Mohapatra, Ph.D., assuming the
role of Chairman of the Board in addition to serving as President and Chief
Executive Officer. The change became effective after Kenneth W. Freeman
stepped down as Chairman of the Board yesterday.
The Board also elected Gary M. Pfeiffer to serve as a Director,
maintaining the Board at 10 members. Mr. Pfeiffer is Senior Vice President
and Chief Financial Officer of E. I. du Pont de Nemours and Company (DuPont).
Mr. Pfeiffer joined DuPont in 1974, where he has held positions of increasing
responsibility in finance and international operations, as well as in various
DuPont divisions. Mr. Pfeiffer also serves as a Director of Talbots Inc.
"We are excited to welcome Gary Pfeiffer to our Board as a new Director,"
said Dr. Mohapatra, Chairman and Chief Executive Officer of Quest Diagnostics.
"Gary's deep financial expertise combined with his global experience and
proven leadership in supporting innovation will make him a valued addition to
our Board."
Quest Diagnostics Incorporated is the nation's leading provider of
diagnostic testing, information and services, providing insights that enable
healthcare professionals to make decisions that improve health. The company
offers the broadest access to diagnostic testing services through its national
network of laboratories and patient service centers, and provides interpretive
consultation through its extensive medical and scientific staff. Quest
Diagnostics is the leading provider of esoteric testing, including gene-based
medical testing, and provides advanced information technology solutions to
improve patient care. Additional company information is available at:
http://www.questdiagnostics.com.
The statements in this press release, which are not historical facts or
information, may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2003 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
-0- 12/15/2004
/CONTACT: Investors: Laure Park, +1-201-393-5030, Media: Gary Samuels,
+1-201-393-5700, both of Quest Diagnostics Incorporated /
/Web site: http://www.questdiagnostics.com /
(DGX)